Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous dexmedetomidine versus ketamine for agitation in bipolar disorder
IRCT20251123068088N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of dexmedetomidine and ketamine in bipolar disorder (BD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Level of agitation. Started Dec 2025; status: completed.
02
Drugs
dexmedetomidineketamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20251123068088N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251123068088N1.